Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.32
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsPremera Bluecross PsA Coverage Update | OpenPayer
    Ask Trek AI about this page
    CurrentPremera BluecrossPolicy N/A

    Drugs Subject to Site of Service Review Addressed in This Policy

    Customize your policy alerts

    Sign up for all Premera Bluecross policy alerts

    Know when Premera Bluecross releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-necessity, site-of-service, and step-therapy requirements for biologic and other drug treatments for active psoriatic arthritis. Site-of-service review applies to members age 13 and older, except Alaska fully insured members; infusion and injection medical-necessity review applies to all ages.

    Policy Summary
    PayerPremera Bluecross
    PolicyDrugs Subject to Site of Service Review Addressed in This Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionDocument active psoriatic arthritis, patient age, inadequate response or intolerance to required prior agents, and rheumatologist or dermatologist prescribing or consultation.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    13+Site-of-service review begins
    90 daysPreferred site period for initial or reinitiated therapy
    50 milesAccess distance threshold
    2Step-therapy tiers

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    SotyktuFirst-line therapy
    AdalimumabSecond-line therapy

    Medical Necessity Criteria

    Site-of-service medical necessity

    Covered when the administration site meets the applicable medical-necessity requirements.

    Preferred sites: Administration is medically necessary in a physician's office, infusion center, or home infusion setting.
    Hospital-based outpatient exception: Hospital-based outpatient administration may be medically necessary during the first 90 days of an initial course or re-initiation after at least 6 months, when no outpatient infusion center is within 50 miles and no contracted home infusion agency will travel to the home, when the hospital is the only site offering the drug, or when a qualifying clinical risk factor or grade 3 or 4 cytokine release syndrome is present.

    For grade 3 or 4 cytokine release syndrome, admission to an inpatient setting is required as soon as possible.

    Adalimumab medical necessity

    Covered when ALL of the following are met.

    Adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Biologic therapy by age and specialist

    Covered when ALL of the following are met.

    Selected biologic agents: The individual has active psoriatic arthritis, meets the drug-specific minimum age, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Avsola, Inflectra, Renflexis, Enbrel, and Taltz: 18 years or older; Simponi Aria and Immgolis Intri: 2 years or older; Steqeyma and Yesintek: 6 years or older

    IL-23 inhibitors

    Covered when ALL of the following are met.

    IL-23 inhibitor therapy: For Tremfya, the individual is aged 6 years or older, weighs at least 40 kg, and the medication is prescribed by or in consultation with a dermatologist or rheumatologist. For Skyrizi, the individual is aged 6 years or older and the medication is prescribed by or in consultation with a dermatologist or rheumatologist.Tremfya: age 6 years or older and weight at least 40 kg; Skyrizi: age 6 years or older

    Janus kinase inhibitors

    Covered when ALL of the following are met.

    JAK inhibitor therapy: For Rinvoq, Rinvoq LQ, tofacitinib, or Xeljanz, the individual is aged 2 years or older, has had an inadequate response or intolerance to one or more TNF blockers, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist. Extended-release tofacitinib or Xeljanz XR requires age 18 years or older in addition to these requirements.Age 2 years or older for non-extended-release products; age 18 years or older for extended-release products

    PDE-4 inhibitors

    Covered when ALL of the following are met.

    PDE-4 inhibitor therapy: For Otezla, the individual is aged 6 years or older, weighs at least 20 kg, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist. For Otezla XR, the individual is aged 6 years or older, weighs at least 50 kg, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Otezla: age 6 years or older and weight at least 20 kg; Otezla XR: age 6 years or older and weight at least 50 kg

    TYK2 inhibitor

    Covered when ALL of the following are met.

    Sotyktu: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu is a first-line TYK2 inhibitor.

    Second-line TNF-alpha antagonists

    Covered when ALL of the following are met.

    Second-line TNF-alpha antagonists: Abrilada, adalimumab-aacf, adalimumab-adbm with NDCs starting 82009, adalimumab-bwwd, adalimumab-fkjp, adalimumab-ryvk, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Simlandi, and Yusimry may be medically necessary for active psoriatic arthritis when the individual is aged 18 years or older.Age 18 years or older

    These agents are identified as second-line TNF-alpha antagonists.

    IL-12/23 inhibitor sequencing

    Covered when ALL of the following are met.

    Stelara: The medication is prescribed by or in consultation with a rheumatologist or dermatologist and the individual has had an inadequate response or intolerance to both Steqeyma and Yesintek.

    This applies to individuals not previously treated with the requested IL-23 inhibitor.

    Adalimumab second-line therapy

    Covered when ALL of the following are met.

    Eligibility criteria

    • Age: The individual is aged 18 years or older.>= 18 years
    • Specialist involvement: The medication is prescribed by or in consultation with a rheumatologist or dermatologist.

    Step-therapy tiers

    The policy establishes the following sequence.

    Therapy sequence

    • First line: Sotyktu (deucravacitinib) is in the first-line TYK2 inhibitor tier.
    • Second line: The specified adalimumab products are in the second-line TNF-alpha antagonist tier.

    Active psoriatic arthritis

    Covered when ALL of the following are met.

    Adult active psoriatic arthritis criteria: The individual is aged 18 years or older, the medication is prescribed by or in consultation with a rheumatologist or dermatologist, and the applicable step-therapy tier is followed.Age 18 years or older; active psoriatic arthritis

    First-line Sotyktu

    Covered when ALL of the following are met.

    Sotyktu criteria: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu is first-line TYK2 therapy.

    Second-line adalimumab products

    Covered when ALL of the following are met.

    Adalimumab criteria: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    The products are second-line TNF-alpha antagonists.

    Initial therapy: Sotyktu

    Covered when ALL of the following are met.

    First-line Sotyktu criteria: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Second-line therapy: adalimumab products

    Covered when ALL of the following are met.

    Second-line adalimumab criteria: The individual has active psoriatic arthritis, is aged 18 years or older, has had an inadequate response or intolerance to all required prerequisite therapies, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    All required prerequisite therapies must be addressed.

    Initial therapy: Sotyktu

    Covered when ALL of the following are met.

    First-line Sotyktu: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu is first-line TYK2 therapy.

    Second-line therapy: adalimumab products

    Covered when ALL of the following are met.

    Second-line adalimumab therapy: The individual has active psoriatic arthritis, is aged 18 years or older, has had an inadequate response or intolerance to all required preceding agents, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Adalimumab products for active psoriatic arthritis

    Covered when ALL of the following are met.

    Adalimumab criteria: The individual has active psoriatic arthritis, is aged 18 years or older, has had an inadequate response or intolerance to all required preceding agents, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu first-line therapy

    The policy identifies the following tier.

    Sotyktu first-line tier: Sotyktu (deucravacitinib) is listed as a first-line TYK2 inhibitor for active psoriatic arthritis.First line

    Adalimumab treatment criteria

    Covered when ALL of the following are met.

    Adalimumab criteria: The individual has active psoriatic arthritis, is aged 18 years or older, has had an inadequate response or intolerance to all required preceding agents, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Adalimumab for active psoriatic arthritis

    Covered when ALL of the following are met.

    Adalimumab criteria: The individual has active psoriatic arthritis, is aged 18 years or older, has had an inadequate response or intolerance to all required prior agents, including adalimumab-aaty, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Step-therapy tier sequence

    The required sequence is as follows.

    Therapy tier sequence

    • First line: TYK2 inhibitors, including Sotyktu, are first line.
    • Second line: TNF-alpha antagonists, including the specified adalimumab products, are second line.

    Second-line adalimumab therapy

    Covered when ALL of the following are met.

    Second-line adalimumab criteria

    • Adult age: The individual is aged 18 years or older.>= 18 years
    • Prerequisite therapy: The individual has had an inadequate response or intolerance to adalimumab-aaty and adalimumab-adaz.Failure or intolerance to all listed agents
    • Specialist involvement: The medication is prescribed by or in consultation with a rheumatologist or dermatologist.

    Active psoriatic arthritis — listed adalimumab products

    Covered when ALL of the following are met.

    Adult active psoriatic arthritis criteria

    • Indication and age: The individual has active psoriatic arthritis and is aged 18 years or older.Age 18 years or older
    • Required prerequisites: The individual has had an inadequate response or intolerance to both adalimumab-aaty and adalimumab-adaz.Both agents required

    Adult active psoriatic arthritis criteria

    Covered when ALL of the following are met.

    Adult age and prior-treatment criteria

    • Age: The individual is aged 18 years or older.>= 18 years
    • Required prior agents: The individual has had an inadequate response or intolerance to both adalimumab-aaty and adalimumab-adaz.Both agents required

    Adalimumab products for active psoriatic arthritis

    Covered when ALL of the following are met.

    Adult age and prior-agent requirements

    • Age: The individual is aged 18 years or older.>= 18 years
    • Prior therapy: The individual has had an inadequate response or intolerance to all required prior agents, including adalimumab-aaty and adalimumab-adaz; one iteration also lists adalimumab-adbm with NDCs starting with 00597.All required agents

    Sotyktu first-line tier

    The policy identifies Sotyktu in the first-line tier.

    First-line TYK2 therapy: Sotyktu (deucravacitinib) is listed in the TYK2 inhibitor first-line tier.First line

    Adalimumab products for active psoriatic arthritis

    Covered when ALL of the following are met.

    Adult active psoriatic arthritis criteria

    • Age: The individual is aged 18 years or older.>= 18 years
    • Prior treatment: The individual has had an inadequate response or intolerance to adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm with NDCs starting with 00597.All 3 agents required

    First-line TYK2 inhibitor

    The policy identifies the first-line therapy tier.

    First-line TYK2 therapy: Sotyktu (deucravacitinib) may be considered medically necessary as a first-line TYK2 inhibitor option.First line

    Active psoriatic arthritis: second-line TNF-alpha antagonists

    Covered when ALL of the following are met.

    Second-line TNF-alpha antagonist criteria

    • Age: The individual is aged 18 years or older.>= 18 years
    • Required prior-agent history: The individual has had an inadequate response or intolerance to adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm with NDCs starting with 00597.All 3 agents required

    Site-of-service medical-necessity review applies only to medical-benefit reviews. Specific intravenous and injectable drugs are reviewed for medical necessity for individuals of all ages; for individuals age 13 and older, the administration site is also reviewed. This site-of-service review does not apply to Alaska fully insured members, who are subject to the infusion and injection drug medical-necessity criteria only.

    Infusion and injectable therapy services may be considered not medically necessary when the applicable site-of-service criteria are not met.

    Drug Identifiers and Thresholds

    NDC identifier referenced in criteriaNDC
    00597NDCs starting with 00597 for adalimumab-adbm
    NDC identifier referenced in criteriaNDC
    82009NDCs starting with 82009 for adalimumab-adbm
    Covered drug identifier qualifierNDCCovered
    NDCs starting with 82009Adalimumab-adbm
    NDC identifier referenced in covered drug listingNDC
    NDCs starting with 82009Adalimumab-adbm products identified by NDCs starting with 82009
    Specified NDC prefixNDC
    NDCs starting with 82009Adalimumab-adbm
    NDC identifierNDC
    NDCs starting with 82009Adalimumab-adbm products with NDCs starting with 82009
    NDC identifier referenced for adalimumab-adbmNDC
    NDCs starting with 82009Adalimumab-adbm
    Additional NDC identifier referenced for prior therapyNDC
    NDCs starting with 00597Adalimumab-adbm
    NDC identifiers referenced in step therapyNDC
    NDCs starting with 82009Adalimumab-adbm products identified by NDCs starting with 82009
    NDCs starting with 00597Adalimumab-adbm products identified as a required prior agent by NDCs starting with 00597
    NDC-specific adalimumab productNDC
    NDCs starting with 82009Adalimumab-adbm product identification specified by NDCs starting with 82009
    NDC-specific required prior agentNDC
    NDCs starting with 00597Adalimumab-adbm product identification specified among required prior agents

    Authorization and Documentation Requirements

    Billing Rule

    Medical Benefit and Site-of-Service Review

    For medical-benefit reviews, document the drug and administration setting. Site-of-service review applies only to members age 13 or older and does not apply to Alaska fully insured members; use infusion and injection medical-necessity criteria for Alaska members.

    • Preferred settings include a physician office, infusion center, or home infusion.
    • Hospital-based outpatient administration requires a qualifying exception.
    Prior Authorization

    Drug-Specific Medical Necessity

    Document active psoriatic arthritis and the drug-specific medical-necessity criteria before requesting authorization.

    Initial and Sequenced Therapy

    Initial drug therapy

    Initial therapy may be considered medically necessary when the drug-specific criteria are met.

    Common initial requirements: The requested medication is being used for active psoriatic arthritis, the applicable minimum age and any weight requirements are met, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist; some agents additionally require inadequate response or intolerance to specified prior therapy.

    Sotyktu first line

    Sotyktu may be considered medically necessary as first-line therapy.

    First-line TYK2 therapy: Sotyktu (deucravacitinib) is listed in the first-line TYK2 inhibitor tier for active psoriatic arthritis.First line

    Adalimumab second line

    Therapeutic Sequence

    StepTherapy tierRequirement
    1JAK inhibitors — first lineRinvoq, Rinvoq LQ, tofacitinib, Xeljanz, tofacitinib extended-release, and Xeljanz XR require inadequate response or intolerance to one or more TNF blockers; product-specific age and specialist requirements apply.
    StepTherapy tierRequirement
    1IL-12/23 inhibitor — first lineFor individuals not previously treated with the requested IL-23 inhibitor, Stelara requires inadequate response or intolerance to both Steqeyma and Yesintek.
    StepTherapy tierAgents or classes
    1First lineTNF-alpha inhibitors; IL-17 inhibitors; IL-12/23 inhibitors; IL-23 inhibitors; Janus kinase inhibitors; PDE-4 inhibitors; TYK2 inhibitors.
    2Second lineTNF-alpha antagonists, including the listed adalimumab products.
    StepTherapy tierTherapy
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib)
    StepTherapy tierProducts
    2TNF-alpha antagonist — second lineAbrilada; adalimumab-aacf; adalimumab-adbm with NDCs starting 82009; adalimumab-bwwd; adalimumab-fkjp; adalimumab-ryvk; Amjevita; Cyltezo; Hadlima; Hulio; Humira; Hyrimoz; Simlandi; Yusimry.
    StepTherapy tierTherapy
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib)
    StepTherapy tierProducts
    2TNF-alpha antagonist — second lineAbrilada; adalimumab-aacf; adalimumab-adbm with NDCs starting 82009; adalimumab-bwwd; adalimumab-fkjp; adalimumab-ryvk; Amjevita; Cyltezo; Hadlima; Hulio; Humira; Hyrimoz; Simlandi; Yusimry.
    StepTherapy tierTherapy
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib)
    2TNF-alpha antagonist — second lineListed adalimumab products.
    StepTherapy tierProducts
    2TNF-alpha antagonist — second lineListed adalimumab products.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineUse or evaluate Sotyktu (deucravacitinib) before second-line adalimumab products, subject to policy criteria.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineListed adalimumab products for active psoriatic arthritis; inadequate response or intolerance to all required prerequisite therapies is required.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib) precedes second-line adalimumab TNF-alpha antagonists.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineListed adalimumab products for adults aged 18 years or older; prescribing or consultation by a rheumatologist or dermatologist is required.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineThe TYK2 inhibitor tier must precede the TNF-alpha antagonist second-line tier.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineFor active psoriatic arthritis, listed adalimumab products require age 18 years or older, inadequate response or intolerance to all required preceding agents, and specialist prescribing or consultation.
    StepTherapy tierRequirement
    1TYK2 inhibitors — first lineTYK2 inhibitors, including Sotyktu, are used before TNF-alpha antagonists.
    2TNF-alpha antagonists — second lineListed adalimumab products follow the first-line tier.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineListed adalimumab products for active psoriatic arthritis; age 18 years or older, inadequate response or intolerance to all required preceding agents, and specialist prescribing or consultation apply.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineUse the first-line TYK2 inhibitor tier before the second-line TNF-alpha antagonist tier.
    StepTherapy tierProducts
    2TNF-alpha antagonist — second lineSpecified adalimumab products.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineUse or trial first-line therapy before second-line TNF-alpha antagonist therapy.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineListed adalimumab products require age 18 years or older, inadequate response or intolerance to adalimumab-aaty and adalimumab-adaz, and rheumatologist or dermatologist prescribing or consultation.
    StepTherapy tierTherapy
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib)
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineListed adalimumab products require inadequate response or intolerance to both adalimumab-aaty and adalimumab-adaz.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib) precedes specified adalimumab TNF-alpha antagonists.
    2TNF-alpha antagonist — second lineSpecified adalimumab products.
    StepTherapy tierPrior-agent requirement
    2TNF-alpha antagonist — second lineInadequate response or intolerance to both adalimumab-aaty and adalimumab-adaz.
    StepTherapy tierRequirement
    1TYK2 inhibitor — first lineUse or evaluate Sotyktu before listed second-line TNF-alpha antagonist products.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineListed adalimumab products require age 18 years or older and inadequate response or intolerance to all required prior agents, including adalimumab-aaty, adalimumab-adaz, and, in one listed iteration, adalimumab-adbm with NDCs starting 00597.
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineTNF-alpha antagonists are listed in the second-line tier; inadequate response or intolerance is required.
    StepTherapy tierTherapy
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib)
    StepTherapy tierTherapy
    1TYK2 inhibitor — first lineSotyktu (deucravacitinib)
    StepTherapy tierRequirement
    2TNF-alpha antagonist — second lineFor active psoriatic arthritis, age 18 years or older and inadequate response or intolerance to all three required agents: adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm with NDCs starting 00597.

    Administration Setting Requirements

    Note

    Prefer physician-office administration

    Use a physician’s office as a preferred medically necessary site for specified IV and injectable drugs when appropriate.

    Note

    Use an infusion center when appropriate

    An infusion center is a preferred medically necessary site for specified IV and injectable drugs.

    Note

    Use home infusion when available

    Use home infusion as a preferred medically necessary site when clinically appropriate and available.

    Reference and Biosimilar Products

    Billing Rule

    Apply Humira second-line criteria

    Humira (adalimumab) is listed in the second-line TNF-alpha antagonist tier. For active psoriatic arthritis, coverage requires the applicable age and prior-therapy criteria.

    Billing Rule

    Review infliximab site of service

    Avsola, Inflectra, and Renflexis are IV infliximab products subject to site-of-service administration review.

    Policy Summary
    PayerPremera Bluecross
    PolicyDrugs Subject to Site of Service Review Addressed in This Policy
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateOctober 1, 2026
    Last ReviewSep 8, 2026
    Next Review DateN/A
    Key ActionDocument active psoriatic arthritis, patient age, inadequate response or intolerance to required prior agents, and rheumatologist or dermatologist prescribing or consultation.
    SourceLink
    On This Page
    Medical Necessity CriteriaDrug Identifiers and ThresholdsAuthorization and Documentation RequirementsInitial and Sequenced TherapyTherapeutic SequenceAdministration Setting RequirementsReference and Biosimilar Products
  1. Confirm the member meets the applicable age requirement.
  2. Document prescribing by, or consultation with, a rheumatologist or dermatologist.
  3. For applicable second-line adalimumab products, document inadequate response or intolerance to all required prerequisite agents.
  4. Documentation Required

    Clinical Eligibility

    Verify clinical eligibility for the requested product, including the applicable age threshold and specialist involvement.

    • Many specified products require age 18 or older.
    • Some products have different pediatric thresholds; apply the product-specific criterion.
    • Document rheumatologist or dermatologist prescribing or consultation when required.
    Prior Authorization

    Core Authorization Requirements

    A complete authorization request must establish age, active psoriatic arthritis, and qualified specialist prescribing or consultation.

    • Include diagnosis and clinical records supporting active disease.
    • Identify the requested product and route of administration.
    • Include relevant prior-treatment history when step therapy applies.
    Step Therapy

    Meet Step-Therapy Requirements

    Meet the required step-therapy criteria before requesting second-line TNF-alpha antagonist therapy.

    • Document inadequate response or intolerance to the required prior agents.
    • For the specified adalimumab products, document failure or intolerance to Adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm with NDCs beginning 00597, as applicable.
    • Include treatment dates, outcomes, and reasons for discontinuation.
    Prior Authorization

    Step Therapy Authorization

    Authorization for specified drugs requires documentation of active psoriatic arthritis, the member’s age, prior therapy, and specialist prescribing.

    • Use the product-specific age requirement.
    • Document rheumatologist or dermatologist involvement.
    • Attach clinical records supporting medical necessity.
    Step Therapy

    Required Step-Therapy Sequence

    Follow the required sequence: Sotyktu (deucravacitinib), a TYK2 inhibitor, is first line; listed adalimumab TNF-alpha antagonists are second line.

    • Do not bypass first-line Sotyktu without documenting inadequate response or intolerance.
    • Document the required sequence in the authorization request.
    Step Therapy

    Therapeutic Tiering

    Therapeutic tiering places Sotyktu first and specified adalimumab products second for the applicable active psoriatic arthritis pathway.

    • First line: TYK2 inhibitor Sotyktu (deucravacitinib).
    • Second line: listed adalimumab products, including Abrilada, adalimumab-aacf, adalimumab-adbm with NDCs beginning 82009, adalimumab-bwwd, adalimumab-fkjp, adalimumab-ryvk, Amjevita, Cyltezo, Hadlima, Hulio, Humira, Hyrimoz, Simlandi, and Yusimry.
    Step Therapy

    First-Line Sotyktu

    Sotyktu may be considered medically necessary for active psoriatic arthritis when the individual is age 18 or older and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.

    • Document the diagnosis, age, and specialist relationship.
    • Record Sotyktu as the first-line TYK2 therapy when the sequence applies.
    Step Therapy

    Second-Line Adalimumab

    The specified adalimumab products are second-line TNF-alpha antagonist therapy for active psoriatic arthritis when applicable prerequisites are met.

    • Confirm age 18 or older.
    • Document inadequate response or intolerance to all required prerequisite agents.
    • Document specialist prescribing or consultation.
    Step Therapy

    Sotyktu Before Adalimumab

    Sotyktu is the first-line TYK2 inhibitor in the specified psoriatic arthritis pathway and must precede listed second-line adalimumab products unless the policy permits otherwise.

    • Document Sotyktu use, failure, or intolerance before requesting second-line therapy.
    • Include specialist documentation.
    Step Therapy

    TYK2 First Line; TNF-Alpha Second Line

    Before second-line TNF-alpha antagonist therapy, document first-line TYK2 treatment and the required clinical outcome.

    • First line: Sotyktu (deucravacitinib).
    • Second line: listed adalimumab products.
    • Record inadequate response or intolerance and treatment dates.
    Documentation Required

    Step-Therapy History

    Maintain a complete step-therapy history showing each required agent, dates of use, response, intolerance, and discontinuation rationale.

    • Include Sotyktu history for the first-line requirement.
    • Include all applicable adalimumab prerequisite history.
    Documentation Required

    Site-of-Service Exception Documentation

    If requesting hospital-based outpatient administration, document the applicable site-of-service exception.

    • Initial course or re-initiation after at least 6 months may qualify for the hospital setting for the first 90 days.
    • Document no outpatient infusion center within 50 miles and no contracted home-infusion agency able to travel, or that the hospital is the only site offering the drug.
    • Document qualifying clinical risk, such as unstable cardiac, pulmonary, or renal disease; difficult vascular access; cognitive or acute mental-status concerns; or prior severe reaction/anaphylaxis.
    • For grade 3 or 4 cytokine-release syndrome, document required temperature, vasopressor, and oxygen/positive-pressure findings and planned prompt inpatient admission.
    Documentation Required

    Eligibility and Prescriber Documentation

    Submit eligibility and prescriber documentation with every applicable request.

    • Member age and plan applicability.
    • Active psoriatic arthritis diagnosis.
    • Rheumatologist or dermatologist prescribing or consultation.
    Documentation Required

    Diagnosis and Step-Therapy Documentation

    Document the diagnosis and the complete step-therapy record supporting the requested product.

    • Identify active psoriatic arthritis.
    • List prerequisite agents, outcomes, and intolerance or failure.
    • Identify requested product and route.
    Documentation Required

    Age and Specialist Documentation

    Provide age and specialist documentation matched to the requested drug’s criterion.

    • Use the product-specific minimum age.
    • Identify the rheumatologist or dermatologist and the prescribing or consultation relationship.
    Documentation Required

    Clinical and Specialist Documentation

    Clinical records must support active disease and qualified specialist involvement.

    • Include examination findings, diagnosis, and treatment rationale.
    • Include specialist notes or consultation documentation.
    Documentation Required

    Required Clinical and Prescribing Documentation

    Include all clinical and prescribing information necessary to evaluate medical necessity.

    • Diagnosis and disease activity.
    • Member age and requested product.
    • Specialist prescriber or consultant.
    • Prior therapy and response, intolerance, or failure.
    Documentation Required

    Required Clinical History

    Document the relevant clinical history, including disease activity, prior treatment, and reasons for any treatment change.

    • Use dates and objective response information when available.
    • Explain intolerance or adverse reactions.
    Documentation Required

    Age and Prior-Agent History

    Record the member’s age and prior-agent history before submitting authorization.

    • Document Sotyktu history for the TYK2-first requirement.
    • Document all required adalimumab prerequisite agents and outcomes.
    Documentation Required

    Diagnosis and Prior Therapy

    Document active psoriatic arthritis and prior therapy supporting the requested treatment tier.

    • Include diagnosis and disease activity.
    • Include agent names, dates, response, intolerance, and discontinuation rationale.
    Step Therapy

    First-Line TYK2; Second-Line TNF Antagonist

    For the applicable pathway, use Sotyktu as first-line therapy and listed adalimumab products as second-line therapy.

    • First-line TYK2 inhibitor: Sotyktu (deucravacitinib).
    • Second-line TNF-alpha antagonists: specified adalimumab products.
    Step Therapy

    First-Line Sotyktu Before Second-Line Adalimumab

    The requested second-line adalimumab product should follow documented first-line Sotyktu therapy or a documented exception based on inadequate response or intolerance.

    • Document the clinical outcome of Sotyktu.
    • Document specialist prescribing or consultation and age 18 or older.
    Step Therapy

    Failure or Intolerance of Required Prerequisites

    Required prerequisite therapy must be documented before second-line authorization.

    • Document inadequate response or intolerance to Adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm with NDCs beginning 00597 when required.
    • Include dates, dose or course information when available, and the clinical reason for stopping.
    Denial Risk

    Site-of-Service Criteria Not Met

    If the site-of-service criteria are not met, infusion or injectable therapy in a nonpreferred setting may be denied as not medically necessary.

    • Preferred settings are physician office, infusion center, or home infusion.
    • Hospital-based outpatient administration requires a documented exception.
    Denial Risk

    Nonpreferred Administration Setting

    For members age 13 or older, review the administration setting; Alaska fully insured members are exempt from SOS review.

    • For Alaska fully insured members, apply infusion and injection medical-necessity criteria only.
    • Document the applicable exception when a nonpreferred setting is requested.
    Denial Risk

    Drug-Specific Criteria Not Met

    Authorization may be denied when age, specialty, active-indication, or prior-treatment requirements for the requested drug are not documented.

    • Confirm active psoriatic arthritis.
    • Apply the product-specific age threshold.
    • Document rheumatologist or dermatologist prescribing or consultation.
    • Document required prior-agent failure or intolerance.
    Denial Risk

    Age or Specialist Requirements Not Met

    Failure to meet the requested product’s age or specialist requirement creates a medical-necessity denial risk.

    • Verify the applicable age threshold.
    • Document qualified specialist prescribing or consultation.
    Denial Risk

    Step Sequence Not Met

    A request may be denied when first-line Sotyktu requirements are not met before second-line therapy is requested.

    • Document Sotyktu use and inadequate response or intolerance, or the applicable policy exception.
    • Do not omit the required sequence.
    Denial Risk

    Eligibility Documentation Deficiency

    Authorization may be denied when age, specialist, diagnosis, or clinical documentation is incomplete.

    • Submit records supporting active psoriatic arthritis.
    • Include age and specialist information.
    Denial Risk

    Core Requirements Not Met

    Requests lacking age, diagnosis, specialist prescriber, or required clinical history may not satisfy core authorization requirements.

    • Include the requested product and route.
    • Include specialist documentation and relevant clinical records.
    Denial Risk

    Required Prior-Therapy Failure or Intolerance

    Required prior therapy must be shown to have failed or been intolerable before applicable second-line therapy is authorized.

    • Document all specified prerequisite agents, not merely one agent.
    • Describe inadequate response or intolerance for each required agent.
    Denial Risk

    Age, Specialist, or Step Requirement Not Met

    Failure to document age, specialist involvement, or the required sequence may result in denial of the requested therapy.

    • Confirm the product-specific age criterion.
    • Document rheumatologist or dermatologist involvement.
    • Document Sotyktu-first sequencing.
    Denial Risk

    Psoriatic Arthritis Step Criteria Not Met

    A request that does not establish the applicable psoriatic arthritis step-therapy criteria may be denied.

    • Document active disease and age.
    • Document first-line Sotyktu history and required second-line prerequisites.
    Denial Risk

    Medical-Necessity Requirements Not Met

    Failure to meet medical-necessity requirements, including diagnosis, age, specialist, or prior-treatment criteria, may result in denial.

    • Submit complete clinical records with the request.
    Denial Risk

    Adalimumab Authorization Requirements Not Met

    Specified adalimumab requests may be denied when age, specialist, or step-therapy requirements are not met.

    • Member must generally be age 18 or older.
    • Document Sotyktu-first sequencing and required prerequisite history.
    • Document rheumatologist or dermatologist prescribing or consultation.
    Denial Risk

    Adult Age and Prerequisite Failure

    Adult age and prerequisite failure criteria must be addressed for second-line adalimumab requests.

    • Document age 18 or older.
    • Document inadequate response or intolerance to all required agents.
    • Document specialist prescribing or consultation.
    Denial Risk

    Age or Step-Therapy Criteria Not Met

    A request may be denied when the member is not within the applicable age range or the required step therapy is not documented.

    • Apply the product-specific age rule.
    • Document Sotyktu and all required prerequisite-agent history.
    Denial Risk

    Age or Step Criteria Not Met

    Second-line adalimumab therapy may be denied when age or required step-therapy criteria are incomplete.

    • Confirm age 18 or older.
    • Document inadequate response or intolerance to all required prerequisite agents.
    Step Therapy

    Therapeutic Tiering

    Use the applicable first-line and second-line tiers when preparing the authorization request.

    • TYK2 first line: Sotyktu (deucravacitinib).
    • TNF-alpha antagonists second line: listed adalimumab products.
    Step Therapy

    First-Line Sotyktu Placement

    Sotyktu (deucravacitinib) is the first-line TYK2 inhibitor for the applicable active psoriatic arthritis pathway.

    • Generally requires age 18 or older.
    • Requires rheumatologist or dermatologist prescribing or consultation.
    Step Therapy

    Second-Line Adalimumab Placement

    Listed adalimumab products occupy the second-line TNF-alpha antagonist tier.

    • Use only after the required first-line and prerequisite history is documented.
    • Confirm age and specialist requirements.
    Step Therapy

    Required Tier Placement

    Document the first-line TYK2 inhibitor before requesting a second-line TNF-alpha antagonist.

    • Sotyktu is first line.
    • Listed adalimumab products are second line.
    Step Therapy

    First-Line TYK2 Followed by Second-Line TNF Antagonist

    The required sequence is Sotyktu first, followed by a listed adalimumab TNF-alpha antagonist when clinically appropriate.

    • Document inadequate response or intolerance to Sotyktu.
    • Document the requested second-line product.
    Step Therapy

    Required Step-Therapy Sequence

    For applicable requests, Sotyktu must precede second-line adalimumab therapy.

    • Include prior Sotyktu treatment history.
    • Explain failure or intolerance before requesting the second-line product.
    Documentation Required

    Required Prerequisite History

    Document failure or intolerance of every required prerequisite before requesting second-line therapy.

    • Include Adalimumab-aaty.
    • Include adalimumab-adaz.
    • Include adalimumab-adbm with NDCs beginning 00597 when applicable.
    Step Therapy

    Second-Line Adalimumab Requirements

    Second-line TNF-alpha antagonist authorization requires the applicable adalimumab products and documentation of age and prior therapy.

    • Confirm age 18 or older.
    • Document inadequate response or intolerance to all required prerequisite agents.
    • Document specialist prescribing or consultation.
    Step Therapy

    First-Line TYK2 Inhibitor Tier

    Sotyktu is the first-line TYK2 tier and should be documented as the initial step in the treatment sequence.

    • Document active psoriatic arthritis.
    • Document age and specialist involvement.
    Step Therapy

    Second-Line TNF-Alpha Antagonists

    The listed adalimumab products are second-line TNF-alpha antagonists after required first-line and prerequisite therapy.

    • Document the applicable product name.
    • Document age 18 or older, specialist involvement, and prior-agent outcomes.
    Documentation Required

    Adalimumab Prerequisite Documentation

    Adalimumab authorization requires documented failure or intolerance of all applicable prerequisites, not just one prior agent.

    • Adalimumab-aaty.
    • Adalimumab-adaz.
    • Adalimumab-adbm with NDCs beginning 00597.
    Denial Risk

    Adult Age and Prerequisite Failure Criteria

    Failure to document adult age or required prerequisite history may result in denial of second-line therapy.

    • Confirm age 18 or older.
    • Document inadequate response or intolerance to every required prerequisite.
    Denial Risk

    Age or Step-Therapy Criteria Not Met

    Requests may be denied when the member does not meet the applicable age or step-therapy requirements.

    • Apply the requested product’s age criterion.
    • Document the complete first-line and prerequisite sequence.
    Denial Risk

    Failure to Meet Age or Step-Therapy Criteria

    Failure to meet age or step-therapy criteria for specified adalimumab products creates a denial risk.

    • Confirm age 18 or older.
    • Document Sotyktu-first treatment and failure or intolerance of all required prerequisite agents.

    Covered when ALL of the following are met.

    Second-line adalimumab therapy: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Active psoriatic arthritis initial therapy

    The following step-therapy tiers apply.

    First-line TYK2 inhibitor: Sotyktu (deucravacitinib) may be considered medically necessary for active psoriatic arthritis when the individual is aged 18 years or older and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older
    Second-line TNF-alpha antagonists: The listed adalimumab products may be considered medically necessary for active psoriatic arthritis when the individual is aged 18 years or older and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu first line

    Covered when ALL of the following are met.

    Initial Sotyktu therapy: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu is first line under TYK2 inhibitors.

    Adalimumab second line

    Covered when ALL of the following are met.

    Second-line adalimumab therapy: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    The products are second-line TNF-alpha antagonists.

    Sotyktu first line

    Covered when ALL of the following are met.

    Sotyktu criteria: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu is first-line TYK2 therapy.

    Adalimumab products second line

    Covered when ALL of the following are met.

    Second-line adalimumab criteria: The individual is aged 18 years or older, has had an inadequate response or intolerance to all required prerequisite therapies, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu initial therapy

    Sotyktu may be considered medically necessary as first-line therapy.

    Sotyktu first-line criteria: The individual has active psoriatic arthritis, is aged 18 years or older, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Adalimumab second-line criteria

    Covered when ALL of the following are met.

    Adalimumab second-line criteria: The individual is aged 18 years or older, has had an inadequate response or intolerance to all required preceding agents, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    Sotyktu first line

    Sotyktu is listed as a TYK2 inhibitor in the first-line tier.

    Sotyktu first-line placement: Sotyktu (deucravacitinib) is identified as first-line therapy in the TYK2 inhibitor tier for active psoriatic arthritis.First line

    Initial step-therapy tiers

    The following tiers apply to active psoriatic arthritis.

    First-line TYK2 inhibitor: Sotyktu (deucravacitinib) is listed as a first-line TYK2 inhibitor.First line
    Second-line TNF-alpha antagonist: The listed adalimumab products are second-line TNF-alpha antagonists for active psoriatic arthritis in individuals aged 18 years or older with inadequate response or intolerance to all required preceding agents and rheumatologist or dermatologist prescribing or consultation.Age 18 years or older

    Sotyktu first line

    Sotyktu is listed in the first-line therapy tier.

    TYK2 inhibitor first line: Sotyktu (deucravacitinib) is listed as a first-line TYK2 inhibitor in the step-therapy sequence.First line

    Adalimumab products second line

    Covered when ALL of the following are met.

    Second-line adalimumab criteria: The individual has active psoriatic arthritis, is aged 18 years or older, has had an inadequate response or intolerance to all required prior agents including adalimumab-aaty, and the medication is prescribed by or in consultation with a rheumatologist or dermatologist.Age 18 years or older

    First-line Sotyktu

    The policy places Sotyktu in the first-line tier.

    First-line TYK2 inhibitor: Sotyktu (deucravacitinib) is listed as a first-line TYK2 inhibitor for active psoriatic arthritis.First line

    Second-line adalimumab products

    Covered when ALL of the following are met.

    Second-line TNF-alpha antagonist

    • Adult age: The individual is aged 18 years or older.>= 18 years
    • Prior therapy: The individual has had an inadequate response or intolerance to adalimumab-aaty and adalimumab-adaz.Failure or intolerance to all listed agents
    • Specialist involvement: The medication is prescribed by or in consultation with a rheumatologist or dermatologist.

    Initial therapy for active psoriatic arthritis

    Covered when ALL of the following are met.

    Initial active psoriatic arthritis criteria

    • Indication and age: The individual has active psoriatic arthritis and is aged 18 years or older.Age 18 years or older
    • Prior therapy: The individual has had an inadequate response or intolerance to both adalimumab-aaty and adalimumab-adaz.Both agents required

    Sotyktu first line

    Sotyktu is listed in the first-line therapy tier.

    First-line TYK2 therapy: Sotyktu (deucravacitinib) is listed as a first-line TYK2 inhibitor.First line

    Adalimumab products second line

    Covered when ALL of the following are met.

    Second-line adalimumab criteria

    • Age: The individual is aged 18 years or older.>= 18 years
    • Prior agents: The individual has had an inadequate response or intolerance to both adalimumab-aaty and adalimumab-adaz.Both agents required

    TYK2 inhibitor first line

    The policy identifies the first-line tier.

    TYK2 inhibitor first line: Sotyktu (deucravacitinib) is listed in the first-line TYK2 inhibitor tier.First line

    Adalimumab initial therapy

    Covered when ALL of the following are met.

    Initial adalimumab therapy: The individual has active psoriatic arthritis, is aged 18 years or older, and has had an inadequate response or intolerance to adalimumab-aaty, adalimumab-adaz, and adalimumab-adbm with NDCs starting with 00597.Age 18 years or older; all 3 prior agents required

    Sotyktu/deucravacitinib — first-line therapy

    Sotyktu is first-line therapy.

    Sotyktu first-line therapy: Sotyktu (deucravacitinib) may be considered medically necessary as a first-line TYK2 inhibitor for active psoriatic arthritis.First line
    Documentation Required

    Document a hospital-outpatient exception

    Hospital-based outpatient administration is medically necessary only when a stated exception applies, such as initial or reinitiated therapy, unavailable outpatient or home infusion access, hospital-only availability, qualifying clinical risk, or grade 3 or 4 cytokine release syndrome with prompt inpatient admission.

    Billing Rule

    Identify the subcutaneous route

    The listed adalimumab products are subcutaneous therapies; document the applicable treatment and administration context for the request.

    Billing Rule

    Use the listed subcutaneous route

    The listed TNF-alpha antagonist products are shown with the subcutaneous route.

    Billing Rule

    Confirm route and setting requirements

    The listed TNF-alpha antagonist products are identified as subcutaneous therapies. The available text does not specify an additional administration-setting rule for these products.